8
Treatment
Table A2: Immunosuppressive Agents
Immunosuppressive
Agents Dosing Indications
Infliximab
(Anti-TNF-α)
5 mg/kg IV, 2
nd
dose may be repeated
14 days later
Severe or steroid-
refractory colitis,
pneumonitis,
myocarditis,
arthritis, nephritis,
uveitis, and
hematological irAEs
Rituximab
(Anti-CD20)
375 mg/m
2
weekly × 4 doses Dermatological
and hematological
irAEs, myositis,
encephalitis, IVIG/
plasmapheresis-
refractory
myasthenia gravis
Tocilizumab
(Anti-IL-6)
8 mg/kg administered intravenously
once per month or 162 mg
administered subcutaneously once
per week.
irAEs refractory to
TNF-α inhibitors
Vedolizumab
(α4/b7 integrin
antagonist)
300 mg IV on weeks 0, 2, 6, and then
every 8 weeks thereaer.
Colitis refractory
to infliximab
or infliximab
contraindicated
Ustekinumab
(Anti-IL-12/IL-23)
Induction: IV:
≤55 kg : 260 mg as single dose
>55 kg to 85 kg : 390 mg as single dose
>85 kg : 520 mg as single dose
Maintenance: SubQ: 90 mg every 8
weeks; begin maintenance dosing 8
weeks aer the IV induction dose.
Colitis
refractory to all
immunosuppression
treatments
(cont'd)
